Article
Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade.
Nature communications - 7 Jun 2021
Khan Zia, Hammer Christian, Carroll Jonathan, Di Nucci Flavia, Acosta Sergio Ley, Maiya Vidya, Bhangale Tushar, Hunkapiller Julie, Mellman Ira, Albert Matthew L, McCarthy Mark I, Chandler G Scott
Abstract excerpt
Activation of systemic immune responses using PD-1 checkpoint inhibitors is an essential approach to cancer therapy. Yet, the extent of benefit relative to risk of immune related adverse events (irAE) varies widely among patients. Here, we study endocrine irAE from 7 clinical trials across 6 cancers where atezolizumab (anti-PD-L1) was combined with chemotherapies and compared to standard of care. We show that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
